Search results
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo Finance· 6 hours agoTaysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a...
Pfizer hemophilia gene therapy arrives in US to uncertain future
BioPharma Dive via Yahoo Finance· 6 days agoThey were also important test cases for the economic viability of gene therapies — pitched as...
Gene therapy center takes big step against Parkinson's disease
Hardwood Paroxysm· 4 days agoIn San Sebastia (Euscade) there is the first large gene therapy center not only in Spain, but also...
Bobby Gaspar
Time Magazine· 8 hours agoDr. Bobby Gaspar, CEO of Orchard Therapeutics, has the dubious honor of making the most expensive medicine—at $4.5 million per dose—currently on the...
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 10 hours agoBefore I begin, let me provide you with an update. As you know, we have submitted a BLA supplement to expand the labeled population for our Duchenne gene therapy& ...
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
InvestorPlace· 10 hours agoPay close attention to gene editing stocks. All in an effort to help treat sickle-cell anemia,...
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 4 days agoIn the last few decades, the rise in cell and gene therapy development has brought about several...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop...
The West Side Index & Gustine Press-Standard· 18 hours agoPoseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 1 day agoGenprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will ...
Taysha Gene Therapies Inc (TSHA) receives an Overweight rating from Piper Sandler – Knox Daily
Knox Daily· 3 days agoAs a result of the transaction, Manning Paul B now holds 16,466,667 shares, worth roughly $39.36 million. Piper Sandler initiated its Taysha Gene Therapies Inc [TSHA] rating ...
